

Study Newsletter 10

February 2025



Congratulations to all Participating Sites: Successfully captured information of more than **1000** patients!

MESSAGE FROM THE STUDY CHAIR

Dear Investigators,

We are thrilled to announce that information for over 1000 patients was successfully captured by the closing date of 31 January 2025.

Our heartfelt thanks go out to all the participating sites for their tremendous effort and dedication in making this study a success thus far.

Regards,

Karen Sliwa (THESUS-HF II Principal Investigator)



Well done to those who have completed the 7 Days recruitment process, for the remaining please complete and enter all new patients on REDCap by end of February 2025

SITE INFORMATION

Thank you for all that completed the site information, sites who have not uploaded their site information yet, please do so by end of February 2025



INVESTIGATORS NOTICE

Thank you to the many sites that submitted their **site information.** For the outstanding sites, please supply any available information on the **REDCap platform, any outstanding information can still be added.** The ESC abstract preparation will conclude 15 February 2025

CLICK HERE to access REDCap Portal Login

UPTITRATION SUB-STUDY REDCap PORTAL NOW OPEN

Usage and Dosing of Guideline-Directed Medical Therapies in African Patients with Heart Failure with Reduced and Mildly Reduced Ejection Fraction

Guidelines recommend starting and quickly increasing guideline-directed medical therapy (GDMT) within six weeks of heart failure (HF) hospitalization to reduce rehospitalization and mortality risk. However, there is a gap between these recommendations and actual practices, leaving many patients with HFrEF and HFmrEF in Africa on suboptimal

therapy. This Sub-study aims to:

- 1. Assess the proportion of HFrEF and HFmrEF patients initiating ACEI/ARB/ARNI, MRA, beta-blockers, and SGLT2i before hospital discharge.
- 2. Evaluate initiation of these medications within 30 days of discharge.
- 3. Evaluate initiation within 60 days of discharge.


K

4. Determine the proportion achieving target doses of ACEI/ARB/ARNI, MRA, and beta blockers at 180 days post-discharge compared to baseline.

CLICK HERE to complete Sub-Study information on REDCap



Congratulations to all participating sites





Hospital, Nigeria





Buea Regional Hospital, Cameroon





Nigeria

ſſ **Tikur Anbessa** Specialized Hospital Ethiopia











Centre of Excellency Cardiovascular Sciences Mloganzila Hospital, Tanzania



Rasheed Shekoni Federal University **Teaching Hospital** Nigeria





Dr Sadiq Ringim and Co-investigator Dr Sabiu Mohammed Hamza with the patient.



Komfo Anokye

Teaching Hospital

Ghana





Bugando Medical Centre, Tanzania













Dr Demu Tesfaye , Dr Birhanu Diriba , Dr Ahmed Yesuf ,Dr Alayu and Dr Natanan with the patient.



Dessie Comprehensive Specialized Hospital Ethiopia



Olabisi Onabanjo University Teaching Hospital, Nigeria



University of Maiduguri **Teaching Hospital** Nigeria

(4)

Security Forces

Hospital, Tunisia

Aminu Kano Teaching Hospital, Nigeria

Hawassa University Hospital, Ethiopia















Uniosun Teaching Hospital, Nigeria



Lagos University **Teaching Hospital** Nigeria



Maputo Central Hospital Mozambique

























ESUT Teaching Hospital Nigeria



University of Calabar **Teaching Hospital** Nigeria



University of Port-Harcourt Teaching Hospital, Nigeria



ICMC General Hospital Ethiopia





Delta State University **Teaching Hospital** Nigeria



Rivers State University Teaching Hospital Nigeria



Lagos State University **Teaching Hospital** Nigeria



Centre National de Cardiologie Mauritania



Federal Teaching Hospital Gombe Nigeria









Prof Maclean Akpa & Dr Aisha Ajala




















PASCAR THESUS-HF II Study Steering Committee Principal Investigator: Karen Sliwa

Co-investigator: Albertino Damasceno, Charle Viljoen, Mahmoud Sani, Gad Cotter Sub-investigator: Neusa Jessen, Simon Stewart



Connect with PASCAR here